273 related articles for article (PubMed ID: 31039620)
1. Role of Genomic Biomarkers in Increasing Fetal Hemoglobin Levels Upon Hydroxyurea Therapy and in β-Thalassemia Intermedia: A Validation Cohort Study.
Kolliopoulou A; Siamoglou S; John A; Sgourou A; Kourakli A; Symeonidis A; Vlachaki E; Chalkia P; Theodoridou S; Ali BR; Katsila T; Patrinos GP; Papachatzopoulou A
Hemoglobin; 2019 Jan; 43(1):27-33. PubMed ID: 31039620
[TBL] [Abstract][Full Text] [Related]
2. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
[No Abstract] [Full Text] [Related]
3. Hb S/
Belisário AR; Carneiro-Proietti AB; Sabino EC; Araújo A; Loureiro P; Máximo C; Flor-Park MV; Rodrigues DDOW; Ozahata MC; McClure C; Mota RA; Gomes Moura IC; Custer B; Kelly S;
Hemoglobin; 2020 Jan; 44(1):1-9. PubMed ID: 32172616
[TBL] [Abstract][Full Text] [Related]
4. A single nucleotide polymorphism in the HBBP1 gene in the human β-globin locus is associated with a mild β-thalassemia disease phenotype.
Giannopoulou E; Bartsakoulia M; Tafrali C; Kourakli A; Poulas K; Stavrou EF; Papachatzopoulou A; Georgitsi M; Patrinos GP
Hemoglobin; 2012; 36(5):433-45. PubMed ID: 22943111
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
[TBL] [Abstract][Full Text] [Related]
6. Genomic variation in the MAP3K5 gene is associated with β-thalassemia disease severity and hydroxyurea treatment efficacy.
Tafrali C; Paizi A; Borg J; Radmilovic M; Bartsakoulia M; Giannopoulou E; Giannakopoulou O; Stojiljkovic-Petrovic M; Zukic B; Poulas K; Stavrou EF; Lambropoulou P; Kourakli A; Felice AE; Papachatzopoulou A; Philipsen S; Pavlovic S; Georgitsi M; Patrinos GP
Pharmacogenomics; 2013 Apr; 14(5):469-83. PubMed ID: 23556445
[TBL] [Abstract][Full Text] [Related]
7. Ten Years of Routine α- and β-Globin Gene Sequencing in UK Hemoglobinopathy Referrals Reveals 60 Novel Mutations.
Henderson SJ; Timbs AT; McCarthy J; Gallienne AE; Proven M; Rugless MJ; Lopez H; Eglinton J; Dziedzic D; Beardsall M; Khalil MS; Old JM
Hemoglobin; 2016; 40(2):75-84. PubMed ID: 26635043
[TBL] [Abstract][Full Text] [Related]
8. Impact of ZBTB7A hypomethylation and expression patterns on treatment response to hydroxyurea.
Chondrou V; Stavrou EF; Markopoulos G; Kouraklis-Symeonidis A; Fotopoulos V; Symeonidis A; Vlachaki E; Chalkia P; Patrinos GP; Papachatzopoulou A; Sgourou A
Hum Genomics; 2018 Oct; 12(1):45. PubMed ID: 30285874
[TBL] [Abstract][Full Text] [Related]
9. Genomic variants in the ASS1 gene, involved in the nitric oxide biosynthesis and signaling pathway, predict hydroxyurea treatment efficacy in compound sickle cell disease/β-thalassemia patients.
Chalikiopoulou C; Tavianatou AG; Sgourou A; Kourakli A; Kelepouri D; Chrysanthakopoulou M; Kanelaki VK; Mourdoukoutas E; Siamoglou S; John A; Symeonidis A; Ali BR; Katsila T; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2016 Mar; 17(4):393-403. PubMed ID: 26895070
[TBL] [Abstract][Full Text] [Related]
10. Co-heredity of silent CAP + 1570 T>C (HBB:c*96T>C) defect and severe β-thal mutation: a cause of mild β-thalassemia intermedia.
Vinciguerra M; Passarello C; Cassarà F; Leto F; Cannata M; Calvaruso G; Di Maggio R; Renda D; Maggio A; Giambona A
Int J Lab Hematol; 2016 Feb; 38(1):17-26. PubMed ID: 26418075
[TBL] [Abstract][Full Text] [Related]
11. A review of cis-trans interplay between DNA sequences 5' to the (G)gamma- and beta-globin genes among Hb F-Malta-I heterozygotes/homozygotes and beta-thalassemia homozygotes/compound heterozygotes, and the effects of hydroxyurea on the Hb F/F-erythrocyte; the need for large multicenter trials.
Felice AE; Borg J; Pizzuto M; Cassar W; Galdies R; Wettinger SB; Pulis S; Hunter GJ; Caruana MR; Farrugia M; Scerri CA
Hemoglobin; 2007; 31(2):279-88. PubMed ID: 17486512
[TBL] [Abstract][Full Text] [Related]
12. Mild Thalassemia Intermedia Due to Interaction of δβ-Thalassemia with Triplicated α-Globin Genes.
Payán-Pernía S; Bernal Noguera S; Rojas Rodríguez E; Serra Ferrer M; Remacha Sevilla ÁF
Hemoglobin; 2020 Jul; 44(4):294-296. PubMed ID: 32693657
[TBL] [Abstract][Full Text] [Related]
13. Response to hydroxyurea treatment in Iranian transfusion-dependent beta-thalassemia patients.
Yavarian M; Karimi M; Bakker E; Harteveld CL; Giordano PC
Haematologica; 2004 Oct; 89(10):1172-8. PubMed ID: 15477200
[TBL] [Abstract][Full Text] [Related]
14. Report on patients with non transfusion-dependent β-thalassemia major being treated with hydroxyurea attending the Thalassemia Research Center, Sari, Mazandaran Province, Islamic Republic of Iran in 2013.
Kosaryan M; Karami H; Zafari M; Yaghobi N
Hemoglobin; 2014; 38(2):115-8. PubMed ID: 24471558
[TBL] [Abstract][Full Text] [Related]
15. Drug Repurposing: Hydroxyurea Therapy Improves the Transfusion-Free Interval in HbE/Beta-Thalassemia-Major Patients with the
Ghosh D; Panja A; Saha D; Banerjee U; Datta AK; Basu A
Genet Test Mol Biomarkers; 2021 Aug; 25(8):563-570. PubMed ID: 34406845
[No Abstract] [Full Text] [Related]
16. Hydroxyurea-induced hematological response in transfusion-independent beta-thalassemia intermedia: case series and review of literature.
Ehsani MA; Hedayati-Asl AA; Bagheri A; Zeinali S; Rashidi A
Pediatr Hematol Oncol; 2009 Nov; 26(8):560-5. PubMed ID: 19954365
[TBL] [Abstract][Full Text] [Related]
17. KLF10 gene expression is associated with high fetal hemoglobin levels and with response to hydroxyurea treatment in β-hemoglobinopathy patients.
Borg J; Phylactides M; Bartsakoulia M; Tafrali C; Lederer C; Felice AE; Papachatzopoulou A; Kourakli A; Stavrou EF; Christou S; Hou J; Karkabouna S; Lappa-Manakou C; Ozgur Z; van Ijcken W; von Lindern M; Grosveld FG; Georgitsi M; Kleanthous M; Philipsen S; Patrinos GP
Pharmacogenomics; 2012 Oct; 13(13):1487-500. PubMed ID: 23057549
[TBL] [Abstract][Full Text] [Related]
18. Clinical and Molecular Characteristics of Non-Transfusion-Dependent Thalassemia in Kuwait.
Adekile AD; Azab AF; Al-Sharida SI; Al-Nafisi BA; Akbulut N; Marouf RA; Mustafa NY
Hemoglobin; 2015; 39(5):320-6. PubMed ID: 26076396
[TBL] [Abstract][Full Text] [Related]
19. Genetic Background of β-Thalassemia in Northeast Algeria with Assessment of the Thalassemia Severity Score and Description of a new β
Abdaoui W; Benouareth DE; Djenouni A; Renoux C; Grifi F; Gouri A; Athamnia F; Benalioua M; Joly P
Hemoglobin; 2019; 43(4-5):223-228. PubMed ID: 31603010
[TBL] [Abstract][Full Text] [Related]
20. Genotype-phenotype relationship of patients with β-thalassemia taking hydroxyurea: a 13-year experience in Iran.
Karimi M; Haghpanah S; Farhadi A; Yavarian M
Int J Hematol; 2012 Jan; 95(1):51-6. PubMed ID: 22180324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
